Eisai Co., Ltd. announced plans to present its latest research findings on lecanemab, an anti-amyloid beta protofibril antibody for treating Alzheimer’s disease, at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders. The event will take place from March 17-21, 2026, in Copenhagen, Denmark, and online.
The company will feature six presentations, including three oral presentations, highlighting data from a U.S. real-world long-term treatment persistence study and outcomes in apolipoprotein E ε4 homozygous carriers. Additionally, four-year data from the Clarity AD Open-Label Extension trial and a genome-wide association study on genetic variants linked to cognitive decline will be presented as posters.
Eisai will also host an industry-sponsored symposium titled “Continue Life Their Way: Early Intervention in Alzheimer’s Disease.” The symposium will focus on the importance of early intervention and continued treatment in early Alzheimer’s disease, featuring discussions led by four global experts in the field.
Lecanemab, developed in collaboration with BioArctic, is a humanized immunoglobulin gamma monoclonal antibody targeting amyloid-beta. It has been approved in 53 countries, including the United States, China, and Japan. A subcutaneous formulation is under regulatory review in several countries, with a U.S. FDA Priority Review action date set for May 24, 2026.
The ongoing AHEAD 3-45 Phase 3 clinical study, conducted in partnership with the Alzheimer's Clinical Trial Consortium and funded by the National Institute on Aging, is exploring lecanemab’s effects on individuals with preclinical Alzheimer's disease. Additionally, the Tau NexGen clinical study for Dominantly Inherited Alzheimer’s Disease includes lecanemab as a foundational therapy.
Eisai and Biogen have collaborated on the development and commercialization of Alzheimer’s treatments since 2014, with Eisai leading regulatory submissions globally. The company continues to advance its Alzheimer’s disease portfolio, aiming to address the condition through innovative therapeutic approaches.
Comments are closed.